The Risk of Infection Human Papilloma Virus Infection in Acceptors of Depot Medroxyprogesterone Acetate Contraceptions

Abstract

Objective: Cervical cancer is the second most prevalent cancer in
women around the world and the most common cancer in women
causing death. This study aims to analyze the connection between
infection of human papilloma virus (HPV) 16/18 and cervical
changes in the acceptors of Depot Medroxyprogesterone Acetate
(DMPA) Contraceptions and nonacceptors of Depot Medroxyprogesterone
Acetate (DMPA) Contraceptions.
Methods: The research was conducted at the Public Service
Institution of Dr. Wahidin Sudirohusodo hospital, and private
midwife clinics for seven months from December 2015 to June 2016.
The research design is cross-sectional with. The samples were forty
acceptors of Depot Medroxyprogesterone Acetate (DMPA) and forty
non-acceptors of Depot Medroxyprogesterone Acetate (DMPA)
contraception. Prevalence of HPV 16/18 and cervical cytology
changes were examine using the polymerase chain reaction and
liquid base cervical cytology.
Results: The results showed there was no significant relationship
between long-term use of DMPA contraceptives with HPV 16 and 18.
There was no significant relationship between long-term use of
DMPA contraceptives with cervical cytology changes. There was no
significant relationship between HPV 16 and 18 infections with the
occurrence of cervical cytology changes in long-term use of DMPA
contraceptives.
Conclusion: The long-term use of DMPA contraceptive does not
increase the risk of HPV 16 and 18 infections. Also does not cause
cervical cytology changes that lead to cervical malignancy.
Keywords: cervical cytology changes, Depot Medroxyprogesterone
Acetate (DMPA) contraception, HPV 16/18 infection